aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАНateroskleroz-665Research ArticleОБЗОРЫREVIEWSЛипопротеины высокой плотности и аполипопротеин A-I: регуляторная роль и новые терапевтические стратегии лечения атеросклерозаHigh-density lipoprotein, and apolipoprotein A-I: a regulatory role and novel therapeutic strategies for the treatment atherosclerosisПоляковЛ. М.PolyakovL. M.

Лев Михайлович Поляков, д-р мед. наук, проф., зав. лабораторией, зам. директора по научной работе

СО РАМН

ФГБУ «НИИ биохимии»

лаборатория медицинской биотехнологии

630117

ул. Тимакова, 2

Новосибирск

SB RAMS

Federal state budgetary institution "Research Institute of Biochemistry"

630117

st. Timakova, 2

Novosibirsk

plm@soramn.ruПанинЛ. Е.PaninL. E.

Лев Евгеньевич Панин, д-р мед. наук, проф., академик, зав. лабораторией, директор

СО РАМН

ФГБУ «НИИ биохимии»

лаборатория молекулярных механизмов межклеточных взаимодействий

630117

ул. Тимакова, 2

Новосибирск

SB RAMS

Federal state budgetary institution "Research Institute of Biochemistry"

630117

st. Timakova, 2

Novosibirsk

ibch@soramn.ruРАМНRAMS201305042022914253Copyright © Поляков Л.М., Панин Л.Е., 20222022Поляков Л.М., Панин Л.Е.Polyakov L.M., Panin L.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/665

   Рассмотрены функции липопротеинов высокой плотности (ЛПВП), не связанные с обменом липидов, входящих в их состав. Представлены результаты собственных исследований, а также литературные данные, свидетельствующие о важной регуляторной роли. Регуляторные эффекты ЛПВП неразрывно связаны с их антиатерогенными свойствами. Однако необходимо учитывать, что механизм антиатерогенного действия ЛПВП не ограничивается только «обратным» транспортом холестерина от периферических тканей в печень, он определяется многими другими факторами, каждый из которых имеет значение не только в контексте защиты организма от атеросклероза, но и в протективной роли ЛПВП в более широком смысле. ЛПВП оказывают важное противовоспалительное действие, обладают антиоксидантными и антиапоптотическими свойствами, регулируют сосудистый тонус и антикоагулянтную активность, действуют как антимикробные и противовирусные агенты. Подчеркнуто, что понимание молекулярных механизмов регуляторных свойств ЛПВП открывает новые перспективы для развития более эффективных методов лечения данной патологии. Новые стратегии лечения должны включать разработку перспективных терапевтических подходов, модулирующих ЛПВП-метаболизм, что позволит повысить их содержание в крови и улучшить «обратный» транспорт холестерина. Рассмотрены два наиболее перспективных направления – создание и использование рекомбинантных или реконструированных ЛПВП, а также пептидов-миметиков аполипопротеина А-I.

   In the review show the functions of high-density lipoprotein, is not related to the exchange of lipids within them. The results own research, as well as literary evidenced of the important regula tory role. Regulatory effect of HDL is closely related to their antiatherogenic properties. However, it should be noted that the mechanism of action of antiatherogenic HDL is not limited to a “reverse” transport of cholesterol from peripheral tissues to the liver, it is determined by many other factors, all of which is important not only in the context of defense against athe ro sclerosis, but also in the protective role of HDL in a broader sense. The data show that HDL has an important antiinflammatory effect, have antioxidant and antiapoptotic properties, regulate vascular tone and anticoagulant activity, act as antimicrobial and antiviral agents. Due to the urgency of the problem of atherosclerosis in the emphasis that understanding the molecular mechanisms of the regulatory properties of HDL opens up new prospects for the development of more effective treatments for this disease. New treatment strategies should include the development of promising therapeutic approaches that modulate HDL metabolism, which would increase their levels in the blood and improve the “reverse” cholesterol transport. This review deals with, in our opinion, the two most promising areas – is the creation and use of recombinant HDL or reconstructed, as well as peptide-mimetics of apolipoprotein A-I.

атеросклерозлипопротеины высокой плотностиаполипопротеин А-Iрегуляторная рольапоА-I-пептиды-миметикистратегии леченияatherosclerosishigh-density lipoproteinapolipoprotein A-Ithe regulatory role of apoA-I-mimetic peptidestreatment strategiesReferencesBornstein J. Insulin-reversible inhibition of glucose utilization by serum lipoprotein fractions // J. Biol. Chem. 1953. V. 205. P. 513–519.Bornstein J. Insulin-reversible inhibition of glucose utilization by serum lipoprotein fractions // J. Biol. Chem. 1953. V. 205. P. 513–519.Бельченко Д. И. Значение β-липопротеидной фракции сыворотки крови лихорадящих животных в регуляции гексокиназной активности тканей / Д. И. Бельченко // Вопр. мед. химии. – 1967. – Т. 13, № 5. – С. 539–543.Бельченко Д. И. Значение β-липопротеидной фракции сыворотки крови лихорадящих животных в регуляции гексокиназной активности тканей / Д. И. Бельченко // Вопр. мед. химии. – 1967. – Т. 13, № 5. – С. 539–543.Ильин В. С. О зависимости тормозящих гексокиназу свойств β-липопротеидной фракции плазмы от кортизона и инсулина / В. С. Ильин, Г. В. Титова // Вопр. мед. химии. – 1956. – Т. 11, № 4. – С. 243–251.Ильин В. С. О зависимости тормозящих гексокиназу свойств β-липопротеидной фракции плазмы от кортизона и инсулина / В. С. Ильин, Г. В. Титова // Вопр. мед. химии. – 1956. – Т. 11, № 4. – С. 243–251.Панин Л. Е. Изучение взаимоотношений между глюкокортикоидной функцией коры надпочечников и липопротеидами сыворотки крови / Л. Е. Панин, Л. М. Поляков // Бюл. эксперим. биологии и медицины. – 1976. – Т. 85, № 10. – С. 1202–1204.Панин Л. Е. Изучение взаимоотношений между глюкокортикоидной функцией коры надпочечников и липопротеидами сыворотки крови / Л. Е. Панин, Л. М. Поляков // Бюл. эксперим. биологии и медицины. – 1976. – Т. 85, № 10. – С. 1202–1204.Панин Л.Е. Механизм регуляции стероидогенеза в надпочечниках липопротеидами сыворотки крови / Л. Е. Панин, Л. М. Поляков // Бюл. эксперим. биологии и медицины. – 1979. – Т. 88, № 9. – С. 267–269.Панин Л.Е. Механизм регуляции стероидогенеза в надпочечниках липопротеидами сыворотки крови / Л. Е. Панин, Л. М. Поляков // Бюл. эксперим. биологии и медицины. – 1979. – Т. 88, № 9. – С. 267–269.Gwynne J. T., Mahaffee D., Brewer H. B. Jr., Ney R. L. Adrenal cholesterol uptake from plasma lipoproteins: regulation by corticotrophin // Proc. Natl. Acad. Sci. USA. 1976. Vol. 73 (12). P. 4329–4333.Gwynne J. T., Mahaffee D., Brewer H. B. Jr., Ney R. L. Adrenal cholesterol uptake from plasma lipoproteins: regulation by corticotrophin // Proc. Natl. Acad. Sci. USA. 1976. Vol. 73 (12). P. 4329–4333.Gwynne J. T., Hughes T., Hess B. Characterization of high-density lipoprotein binding activity in rat adrenocortical cells // J. Lipid Res. 1984. Vol. 25 (10). P. 1059–1071.Gwynne J. T., Hughes T., Hess B. Characterization of high-density lipoprotein binding activity in rat adrenocortical cells // J. Lipid Res. 1984. Vol. 25 (10). P. 1059–1071.Dyer C. A., Curtiss L. K. Apoprotein E-rich high density lipoproteins inhibit ovarian androgen synthesis // J. Biol. Chem. 1988. Vol. 263 (22). P. 10965–10973.Dyer C. A., Curtiss L. K. Apoprotein E-rich high density lipoproteins inhibit ovarian androgen synthesis // J. Biol. Chem. 1988. Vol. 263 (22). P. 10965–10973.Rajan V. P., Menon K. M. Metabolism of high-density lipoproteins in cultured rat luteal cells // Biochim. Biophys. Acta. 1987. Vol. 921 (1). P. 25–37.Rajan V. P., Menon K. M. Metabolism of high-density lipoproteins in cultured rat luteal cells // Biochim. Biophys. Acta. 1987. Vol. 921 (1). P. 25–37.Plump A. S., Erickson S. K., Weng W., et al. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production // J. Clin. Invest. 1996. Vol. 97 (11). Р. 2660–2671.Plump A. S., Erickson S. K., Weng W., et al. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production // J. Clin. Invest. 1996. Vol. 97 (11). Р. 2660–2671.Brown M. S., Goldstein J. L. Receptor-mediated endocytosis: insights from the lipoprotein receptor system // Proc. Natl. Acad. Sci. USA. 1979. Vol. 76 (7). P. 3330–3337.Brown M. S., Goldstein J. L. Receptor-mediated endocytosis: insights from the lipoprotein receptor system // Proc. Natl. Acad. Sci. USA. 1979. Vol. 76 (7). P. 3330–3337.Панин Л. Е. Влияние кортизола, адреналина и АКТГ на поглощение и внутриклеточное распределение меченных по белку липопротеидов тканями печени и надпочечников крыс / Л. Е. Панин [и др.] // Цитология. – 1981. – № 11. – С. 1257–1263.Панин Л. Е. Влияние кортизола, адреналина и АКТГ на поглощение и внутриклеточное распределение меченных по белку липопротеидов тканями печени и надпочечников крыс / Л. Е. Панин [и др.] // Цитология. – 1981. – № 11. – С. 1257–1263.Панин Л. Е. Поглощение йодированных липопротеидов плазмы крови субпопуляциями гепатоцитов и синусоидными клетками печени крыс / Л. Е. Панин, И. Ф. Усынин, Л. М. Поляков // Вопр. мед. химии. – 1986. – Т. 32, № 4. – С. 106–110.Панин Л. Е. Поглощение йодированных липопротеидов плазмы крови субпопуляциями гепатоцитов и синусоидными клетками печени крыс / Л. Е. Панин, И. Ф. Усынин, Л. М. Поляков // Вопр. мед. химии. – 1986. – Т. 32, № 4. – С. 106–110.Поляков Л. М. Поглощение липопротеидов плазмы крови стероидпродуцирующими органами у крыс Л. М. Поляков, Л. Е. Панин // Пробл. эндокринологии. – 1985. – Т. 31, № 4. – С. 72–75.Поляков Л. М. Поглощение липопротеидов плазмы крови стероидпродуцирующими органами у крыс Л. М. Поляков, Л. Е. Панин // Пробл. эндокринологии. – 1985. – Т. 31, № 4. – С. 72–75.Поляков Л. М.. Внутриклеточное распределение меченых липопротеидов в тканях крыс при физической нагрузке / Л. М. Поляков, Л. Е. Панин // Цитология. – 1991. – Т. 33. – С. 32–37.Поляков Л. М.. Внутриклеточное распределение меченых липопротеидов в тканях крыс при физической нагрузке / Л. М. Поляков, Л. Е. Панин // Цитология. – 1991. – Т. 33. – С. 32–37.Поляков Л. М. Поглощение и внутриклеточное распределение липопротеидов в надпочечниках крыс при физической нагрузке / Л. М. Поляков, Л. Е. Панин, Е. Э. Войцеховская // Пробл. эндокринологии. – 1984. – Т. 30, № 4. – С. 60–63.Поляков Л. М. Поглощение и внутриклеточное распределение липопротеидов в надпочечниках крыс при физической нагрузке / Л. М. Поляков, Л. Е. Панин, Е. Э. Войцеховская // Пробл. эндокринологии. – 1984. – Т. 30, № 4. – С. 60–63.Бернштейн Л. М. Влияние липопротеидов сыворотки крови человека на некоторые показатели тиреоидной функции крыс / Л. М. Бернштейн [и др.] // Пробл. эндокринологии. – 1982. – Т. 28, № 3. – C. 72–76.Бернштейн Л. М. Влияние липопротеидов сыворотки крови человека на некоторые показатели тиреоидной функции крыс / Л. М. Бернштейн [и др.] // Пробл. эндокринологии. – 1982. – Т. 28, № 3. – C. 72–76.Поляков Л. М. Липопротеины плазмы крови: транспортная система для ксенобиотиков и биологически активных веществ / Л. М. Поляков // Бюл. СО РАМН. – 1998. – № 4. – С. 23–29.Поляков Л. М. Липопротеины плазмы крови: транспортная система для ксенобиотиков и биологически активных веществ / Л. М. Поляков // Бюл. СО РАМН. – 1998. – № 4. – С. 23–29.Панин Л. Е. Влияние плазменных липопротеинов на секрецию инсулина островками Лангерганса поджелудочной железы / Л. Е. Панин, О. Н. Потеряева, Г. С. Русских // Бюл. СО РАМН. – 2010. – Т. 30, № 2. – С. 28–32.Панин Л. Е. Влияние плазменных липопротеинов на секрецию инсулина островками Лангерганса поджелудочной железы / Л. Е. Панин, О. Н. Потеряева, Г. С. Русских // Бюл. СО РАМН. – 2010. – Т. 30, № 2. – С. 28–32.Панин Л. Е. Влияние апопротеинов липопротеинов очень низкой и высокой плотности на катионную проницаемость и потенциал внутренней мембраны митохондрий печени крыс / Л. Е. Панин [и др.] // Биол. мембраны. – 1991. – Т. 8, № 7. – С. 743–748.Панин Л. Е. Влияние апопротеинов липопротеинов очень низкой и высокой плотности на катионную проницаемость и потенциал внутренней мембраны митохондрий печени крыс / Л. Е. Панин [и др.] // Биол. мембраны. – 1991. – Т. 8, № 7. – С. 743–748.Панин Л. Е. Кооперативный эффект глюкокортикоидов, адреналина и ЛПВП в регуляции активности гексокиназы печени / Л. Е. Панин, Н. В. Атучина, Т. А. Третьякова // Пробл. эндокринологии. – 1990. – № 2. – С. 83–86.Панин Л. Е. Кооперативный эффект глюкокортикоидов, адреналина и ЛПВП в регуляции активности гексокиназы печени / Л. Е. Панин, Н. В. Атучина, Т. А. Третьякова // Пробл. эндокринологии. – 1990. – № 2. – С. 83–86.Панин Л. Е. О кооперативном эффекте гидрокортизона, адреналина и липопротеидов высокой плотности в регуляции активности глюкозо-6-фосфатдегидрогеназы в печени / Л. Е. Панин, Т. Г. Филатова // Пробл . эндокринологии. – 1986. – № 4. – С. 69–71.Панин Л. Е. О кооперативном эффекте гидрокортизона, адреналина и липопротеидов высокой плотности в регуляции активности глюкозо-6-фосфатдегидрогеназы в печени / Л. Е. Панин, Т. Г. Филатова // Пробл . эндокринологии. – 1986. – № 4. – С. 69–71.Feig J. E., Shamir R., Fisher E. A. Atheroprotective effects of HDL: beyond reverse cholesterol transport // Curr. Drug Targets. 2008. Vol. 9 (3). P. 196–203.Feig J. E., Shamir R., Fisher E. A. Atheroprotective effects of HDL: beyond reverse cholesterol transport // Curr. Drug Targets. 2008. Vol. 9 (3). P. 196–203.Tall A. R. Cholesterol efflux pathways and other potential mechanisms involved in the atheroprotective effect of high density lipoproteins // J. Intern. Med. 2008. Vol. 263 (3). P. 256–273.Tall A. R. Cholesterol efflux pathways and other potential mechanisms involved in the atheroprotective effect of high density lipoproteins // J. Intern. Med. 2008. Vol. 263 (3). P. 256–273.Inankur A., Nicholls S. J., Jahangiri A. High-density lipoprotein: is the good cholesterol turning bad? // Curr. Cardiovasc. Risk Rep. 2011. Vol. 5. P. 18–28.Inankur A., Nicholls S. J., Jahangiri A. High-density lipoprotein: is the good cholesterol turning bad? // Curr. Cardiovasc. Risk Rep. 2011. Vol. 5. P. 18–28.Barter P. J., Nicholls S., Rye K. A., et al. Anti-inflammatory properties of HDL // Circ. Res. 2004. Vol. 95 (8). P. 764–772.Barter P. J., Nicholls S., Rye K. A., et al. Anti-inflammatory properties of HDL // Circ. Res. 2004. Vol. 95 (8). P. 764–772.Murphy A. J., Woollard K. J., Hoang A. et al. Highdensity lipoprotein reduces the human monocyte inflammatory response // Arterioscler. Thromb. Vasc. Biol. 2008. Vol. 28 (11). P. 2071–2077.Murphy A. J., Woollard K. J., Hoang A. et al. Highdensity lipoprotein reduces the human monocyte inflammatory response // Arterioscler. Thromb. Vasc. Biol. 2008. Vol. 28 (11). P. 2071–2077.Murphy A. J., Woollard K. J. High Density Lipoprotein: A Potent Inhibitor of Inflammation // Clin. Exp. Pharmacol. Physiol. 2010. Vol. 37. P. 710–718.Murphy A. J., Woollard K. J. High Density Lipoprotein: A Potent Inhibitor of Inflammation // Clin. Exp. Pharmacol. Physiol. 2010. Vol. 37. P. 710–718.Desanctis J.B., Blanca I., Bianco N. E. Effects of different lipoproteins on the proliferative response of interleukin-2-activated T lymphocytes and large granular lymphocytes // Clin. Sci. 1995. Vol. 89. P. 511–519.Desanctis J.B., Blanca I., Bianco N. E. Effects of different lipoproteins on the proliferative response of interleukin-2-activated T lymphocytes and large granular lymphocytes // Clin. Sci. 1995. Vol. 89. P. 511–519.Desanctis J. B., Blanca I., Bianco N. E. Secretion of cytokines by natural killer cells primed with interleukin-2 and stimulated with different lipoproteins // Immunology. 1997. Vol. 90. P. 526–533.Desanctis J. B., Blanca I., Bianco N. E. Secretion of cytokines by natural killer cells primed with interleukin-2 and stimulated with different lipoproteins // Immunology. 1997. Vol. 90. P. 526–533.Hyka N., Dayer J. M., Modoux C. et al. Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes // Blood. 2001. Vol. 97 (8). P. 2381–2389.Hyka N., Dayer J. M., Modoux C. et al. Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes // Blood. 2001. Vol. 97 (8). P. 2381–2389.Recalde D., Ostos M. A., Badell E. et al. Human apolipoprotein A-IV reduces secretion of proin flammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide // Arte rioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 756–761.Recalde D., Ostos M. A., Badell E. et al. Human apolipoprotein A-IV reduces secretion of proin flammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide // Arte rioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 756–761.Gomaraschi M., Basilico N., Sisto F. et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli // Biochim. Biophys. Acta. 2005. Vol. 1736. P. 136–143.Gomaraschi M., Basilico N., Sisto F. et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli // Biochim. Biophys. Acta. 2005. Vol. 1736. P. 136–143.Cockerill G. W., Rye K., Gamble R. R. et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules // Arterioscler. Thromb. Vasc. Biol. 1995. Vol. 15. P. 1987–1994.Cockerill G. W., Rye K., Gamble R. R. et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules // Arterioscler. Thromb. Vasc. Biol. 1995. Vol. 15. P. 1987–1994.Ashby D. T, Rye K. A, Clay M. A. et al. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells // Arterioscler. Thromb. Vasc. Biol. 1998. Vol. 18 (9). P. 1450–1455.Ashby D. T, Rye K. A, Clay M. A. et al. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells // Arterioscler. Thromb. Vasc. Biol. 1998. Vol. 18 (9). P. 1450–1455.Fidge N. H. High density lipoprotein receptors, binding proteins, and ligands // J. Lipid. Res. 1999. Vol. 40 (2). P. 187–201.Fidge N. H. High density lipoprotein receptors, binding proteins, and ligands // J. Lipid. Res. 1999. Vol. 40 (2). P. 187–201.Kontush A., Chantepie S., Chapman M. J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. 1881–1888.Kontush A., Chantepie S., Chapman M. J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. 1881–1888.Xia P., Vadas M. A., Rye K.-A. et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway: a possible mechanism for protection against atherosclerosis by HDL // J. Biol. Chem. 1999. Vol. 274. P. 33143–33147.Xia P., Vadas M. A., Rye K.-A. et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway: a possible mechanism for protection against atherosclerosis by HDL // J. Biol. Chem. 1999. Vol. 274. P. 33143–33147.Park S. H., Park J. H., Kang J. S., Kang Y. H. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression // Int. J. Biochem. Cell. Biol. 2003. Vol. 35. P.168–182.Park S. H., Park J. H., Kang J. S., Kang Y. H. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression // Int. J. Biochem. Cell. Biol. 2003. Vol. 35. P.168–182.Nofer J.-R., Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids // Trends. Cardiovasc. Med. 2005. Vol. 15. P. 265–271.Nofer J.-R., Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids // Trends. Cardiovasc. Med. 2005. Vol. 15. P. 265–271.Cockerill G. W., Saklatvala J., Ridley S. H. et al. High-density lipoproteins differentially odulate cytokine-induced expression of E-selectin and cyclooxygena - se-2 // Arterioscler. Thromb. Vasc. Biol. 1999. Vol. 19. P. 910–917.Cockerill G. W., Saklatvala J., Ridley S. H. et al. High-density lipoproteins differentially odulate cytokine-induced expression of E-selectin and cyclooxygena - se-2 // Arterioscler. Thromb. Vasc. Biol. 1999. Vol. 19. P. 910–917.Nicholls S. J., Dusting G. J., Cutri B. et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits // Circulation. 2005. Vol. 111. P. 1543–1550.Nicholls S. J., Dusting G. J., Cutri B. et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits // Circulation. 2005. Vol. 111. P. 1543–1550.Liao X. L., Lou B., Ma J., Wu M. P. Neutrophils activation can be diminished by apolipoprotein A-I // Life Sci. 2005. Vol. 77 (3). P. 325–335.Liao X. L., Lou B., Ma J., Wu M. P. Neutrophils activation can be diminished by apolipoprotein A-I // Life Sci. 2005. Vol. 77 (3). P. 325–335.Ulevitch R. J., Johnston A. R., Weinstein D. B. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma // J. Clin. Investig. 1981. Vol. 67. Р. 827–837.Ulevitch R. J., Johnston A. R., Weinstein D. B. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma // J. Clin. Investig. 1981. Vol. 67. Р. 827–837.Massamiri T., Tobias P. S., Curtiss L. K. Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I // J. Lipid. Res. 1997. Vol. 38 (3). Р. 516–525.Massamiri T., Tobias P. S., Curtiss L. K. Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I // J. Lipid. Res. 1997. Vol. 38 (3). Р. 516–525.Cуменкова Д. В. Участие липопротеинов высокой плотности и аполипопротеина А-I в механизмах внутриклеточной регуляции и направленном транспорте биологически активных веществ в клетки: автореф. дис. … д-ра биол. наук / Д. В. Суменкова. – Новосибирск, 2010.Cуменкова Д. В. Участие липопротеинов высокой плотности и аполипопротеина А-I в механизмах внутриклеточной регуляции и направленном транспорте биологически активных веществ в клетки: автореф. дис. … д-ра биол. наук / Д. В. Суменкова. – Новосибирск, 2010.Feingold K. R., Funk J. L., Moser A. H. et al. Role for circulating lipoproteins in protection from endotoxin toxicity // Infect. Immun. 1995. Vol. 63 (5). P. 2041–2046.Feingold K. R., Funk J. L., Moser A. H. et al. Role for circulating lipoproteins in protection from endotoxin toxicity // Infect. Immun. 1995. Vol. 63 (5). P. 2041–2046.Поляков Л. М. Влияние липопротеинов плазмы крови и их комплексов с полисахаридами на содержание интерлейкина-1β в макрофагах мышей с асцитной HA-1 гепатомой / Л. М. Поляков, Д. В. Суменкова, Л. Е. Панин // Бюл. эксперим. биологии и медицины. – 2009. – Т. 147, № 4. – С. 499–451.Поляков Л. М. Влияние липопротеинов плазмы крови и их комплексов с полисахаридами на содержание интерлейкина-1β в макрофагах мышей с асцитной HA-1 гепатомой / Л. М. Поляков, Д. В. Суменкова, Л. Е. Панин // Бюл. эксперим. биологии и медицины. – 2009. – Т. 147, № 4. – С. 499–451.Burger D., Dayer J. M. High-density lipoprotein-as-sociated apolipoprotein A-I: the missing link between infection and chronic inflammation? // Autoimmun. Rev. 2002. Vol. 1. P. 111–117.Burger D., Dayer J. M. High-density lipoprotein-as-sociated apolipoprotein A-I: the missing link between infection and chronic inflammation? // Autoimmun. Rev. 2002. Vol. 1. P. 111–117.Sampietro T., Bigazzi F., Dal Pino B. et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? // Circulation. 2002. Vol. 105. P. 11–14.Sampietro T., Bigazzi F., Dal Pino B. et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? // Circulation. 2002. Vol. 105. P. 11–14.Wadham C., Albanese N., Roberts J. et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity // Circulation. 2004. Vol. 109 (17). P. 2116–2122.Wadham C., Albanese N., Roberts J. et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity // Circulation. 2004. Vol. 109 (17). P. 2116–2122.Lee C. M., Chien C. T., Chang P. Y. et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity // Atherosclerosis. 2005. Vol. 183. P. 251–258.Lee C. M., Chien C. T., Chang P. Y. et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity // Atherosclerosis. 2005. Vol. 183. P. 251–258.Van Lenten B. J., Navab M., Shih D. et al. The role of high-density lipoproteins in oxidation and inflammation // Trends. Cardiovasc. Med. 2001. Vol. 11 (3-4). P. 155–161.Van Lenten B. J., Navab M., Shih D. et al. The role of high-density lipoproteins in oxidation and inflammation // Trends. Cardiovasc. Med. 2001. Vol. 11 (3-4). P. 155–161.Navab M., Ananthramaiah G. M., Reddy S. T. et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL // J. Lipid Res. 2004. Vol. 45. P. 993–1007.Navab M., Ananthramaiah G. M., Reddy S. T. et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL // J. Lipid Res. 2004. Vol. 45. P. 993–1007.Navab M., Yu R., Gharavi N. et al. High-density lipoprotein: antioxidant and anti-inflammatory properties // Curr. Atheroscler. Rep. 2007. Vol. 9 (3). P. 244–248.Navab M., Yu R., Gharavi N. et al. High-density lipoprotein: antioxidant and anti-inflammatory properties // Curr. Atheroscler. Rep. 2007. Vol. 9 (3). P. 244–248.Bowry V. W., Stanley K. K., Stocker R. High-density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors // Proc. Natl. Acad. Sci. USA. 1992. Vol. 89. P. 10316–10320.Bowry V. W., Stanley K. K., Stocker R. High-density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors // Proc. Natl. Acad. Sci. USA. 1992. Vol. 89. P. 10316–10320.Raffai R. L., Loeb S. M., Weisgraber K. H. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 436–441.Raffai R. L., Loeb S. M., Weisgraber K. H. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 436–441.Trougakos I. P., Lourda M., Agiostratidou G. et al. Differential effects of clusterin/apolipoprotein J on cellular growth and survival // Free Radic. Biol. Med. 2005. Vol. 38. P. 436–449.Trougakos I. P., Lourda M., Agiostratidou G. et al. Differential effects of clusterin/apolipoprotein J on cellular growth and survival // Free Radic. Biol. Med. 2005. Vol. 38. P. 436–449.Boisfer E., Stengel D., Pastier D. et al. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II // J. Lipid. Res. 2002. Vol. 43. P. 732–741.Boisfer E., Stengel D., Pastier D. et al. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II // J. Lipid. Res. 2002. Vol. 43. P. 732–741.Ostos M. A., Conconi M., Vergnes L. et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice // Arterioscler. Thromb. Vasc. Biol. 2001. Vol. 21. P. 1023–1028.Ostos M. A., Conconi M., Vergnes L. et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice // Arterioscler. Thromb. Vasc. Biol. 2001. Vol. 21. P. 1023–1028.Rotllan N., Ribas V., Calpe-Berdiel L. et al. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 128–132.Rotllan N., Ribas V., Calpe-Berdiel L. et al. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 128–132.Davidsson P., Hulthe J., Fagerberg B., Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30 (2). P. 156–163.Davidsson P., Hulthe J., Fagerberg B., Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30 (2). P. 156–163.Gaidukov L., Tawfik D. S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I // Biochemistry. 2005. Vol. 44. P. 11843–11854.Gaidukov L., Tawfik D. S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I // Biochemistry. 2005. Vol. 44. P. 11843–11854.Gaidukov L., Bar D., Yacobson S. et al. In vivo administ ration of BL-3050: highly stable engineered PON1-HDL complexes // BMC Clinical Pharmacology. 2009. Vol. 9, article 18.Gaidukov L., Bar D., Yacobson S. et al. In vivo administ ration of BL-3050: highly stable engineered PON1-HDL complexes // BMC Clinical Pharmacology. 2009. Vol. 9, article 18.Gaidukov L., Viji R. I., Yacobson S. et al. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I // Biochemistry. 2010. Vol. 49 (3). P. 532–538.Gaidukov L., Viji R. I., Yacobson S. et al. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I // Biochemistry. 2010. Vol. 49 (3). P. 532–538.James R. W., Deakin S. P. The contribution of high-density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function // Adv. Exp. Med. Biol. 2010. Vol. 660. P. 173–181.James R. W., Deakin S. P. The contribution of high-density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function // Adv. Exp. Med. Biol. 2010. Vol. 660. P. 173–181.Rosenblat M., Vaya J., Shih D., Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine // Athe rosclerosis. 2005. Vol. 179. P. 69–77.Rosenblat M., Vaya J., Shih D., Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine // Athe rosclerosis. 2005. Vol. 179. P. 69–77.Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 923–931.Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 923–931.Arakawa H., Qian J.-Y., Baatar D. et al. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits // Circulation. 2005. Vol. 111. P. 3302–3309.Arakawa H., Qian J.-Y., Baatar D. et al. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits // Circulation. 2005. Vol. 111. P. 3302–3309.Connelly P. W., Draganov D., Maguire G. F. Paraoxonase-1 does not reduce or modify oxidation of phos-pholipids by peroxynitrite // Free Radic. Biol. Med. 2005. Vol. 38. P. 164–174.Connelly P. W., Draganov D., Maguire G. F. Paraoxonase-1 does not reduce or modify oxidation of phos-pholipids by peroxynitrite // Free Radic. Biol. Med. 2005. Vol. 38. P. 164–174.Milochevitch C., Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging // Prostaglandins Leukot. Essent. Fatty. Acids. 2001. Vol. 65 (5-6). P. 241–246.Milochevitch C., Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging // Prostaglandins Leukot. Essent. Fatty. Acids. 2001. Vol. 65 (5-6). P. 241–246.Kontush A., de Faria E. C., Chantepie S., Chapman M. J. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties // Arte rioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 526–533.Kontush A., de Faria E. C., Chantepie S., Chapman M. J. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties // Arte rioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 526–533.Choudhury R. P., Rong J. X., Trogan E. et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 1904–1909.Choudhury R. P., Rong J. X., Trogan E. et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 1904–1909.Moore R. E., Navab M., Millar J. S. et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation // Circ. Res. 2005. Vol. 97. P. 763–771.Moore R. E., Navab M., Millar J. S. et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation // Circ. Res. 2005. Vol. 97. P. 763–771.Andrews K. L., Moore X. L., Chin-Dusting J. P. Antiatherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium // Clin. Exp. Pharmacol. Physiol. 2010. Vol. 37 (7). P. 736–742.Andrews K. L., Moore X. L., Chin-Dusting J. P. Antiatherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium // Clin. Exp. Pharmacol. Physiol. 2010. Vol. 37 (7). P. 736–742.Robbesyn F., Garcia V., Auge N. et al. HDL counter-balance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species, proteasome activation, and subsrquent NF-B activation in smooth muscle cells // FASEB J. 2003. Vol. 17. P. 743–745.Robbesyn F., Garcia V., Auge N. et al. HDL counter-balance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species, proteasome activation, and subsrquent NF-B activation in smooth muscle cells // FASEB J. 2003. Vol. 17. P. 743–745.Kwon Y. G., Min J. K., Kim K. M. et al. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production // J. Biol. Chem. 2001. Vol. 276. P. 10627–10633.Kwon Y. G., Min J. K., Kim K. M. et al. Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production // J. Biol. Chem. 2001. Vol. 276. P. 10627–10633.Li X. A., Titlow W. B., Jackson B. A. et al. High-density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner // J. Biol. Chem. 2002. Vol. 277. P. 11058–11063.Li X. A., Titlow W. B., Jackson B. A. et al. High-density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner // J. Biol. Chem. 2002. Vol. 277. P. 11058–11063.Drew B. G., Fidge N. H., Gallon-Beaumier G., Kemp B. E., Kingwell B. A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. P. 6999–7004.Drew B. G., Fidge N. H., Gallon-Beaumier G., Kemp B. E., Kingwell B. A. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. P. 6999–7004.Noor R., Shuaib U., Wang C. X. et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis // Atherosclerosis. 2007. Vol. 192 (1). P. 92–99.Noor R., Shuaib U., Wang C. X. et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis // Atherosclerosis. 2007. Vol. 192 (1). P. 92–99.Biran S., Horowitz A. T., Fuks Z., Vlodavsky I. High-density lipoprotein and extracellular matrix promotes growth and plating efficiency of normal human mammary epithelial cells in serum-free medium // Int. J. Cancer. 1983. Vol. 31 (5). P. 557–566.Biran S., Horowitz A. T., Fuks Z., Vlodavsky I. High-density lipoprotein and extracellular matrix promotes growth and plating efficiency of normal human mammary epithelial cells in serum-free medium // Int. J. Cancer. 1983. Vol. 31 (5). P. 557–566.Resink T. J., Bochkov V. N., Hahn A. W. et al. Low-and high-density lipoproteins as mitogenic factors for vascular smooth muscle cells: individual, additive and synergistic effects // J. Vasc. Res. 1995. Vol. 32 (5). P. 328–338.Resink T. J., Bochkov V. N., Hahn A. W. et al. Low-and high-density lipoproteins as mitogenic factors for vascular smooth muscle cells: individual, additive and synergistic effects // J. Vasc. Res. 1995. Vol. 32 (5). P. 328–338.Favre G., Blancy E., Tournier J. F., Soula G. Proliferative effect of high density lipoprotein (HDL) and HDL fractions (HDL 1,2, HDL3) on virus transformed lymphoblastoid cells // Biochim. Biophys. Acta. 1989. Vol. 1013 (2). P. 118–124.Favre G., Blancy E., Tournier J. F., Soula G. Proliferative effect of high density lipoprotein (HDL) and HDL fractions (HDL 1,2, HDL3) on virus transformed lymphoblastoid cells // Biochim. Biophys. Acta. 1989. Vol. 1013 (2). P. 118–124.Favre G., Tazi K. A., Le G. F. et al. High density lipoprotein3 binding sites are related to DNA biosynthesis in the adenocarcinoma cell line A549 // J. Lipid. Res. 1993. Vol. 34 (7). Р. 1093–1106.Favre G., Tazi K. A., Le G. F. et al. High density lipoprotein3 binding sites are related to DNA biosynthesis in the adenocarcinoma cell line A549 // J. Lipid. Res. 1993. Vol. 34 (7). Р. 1093–1106.Rotheneder M., Kostner G. M. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines // Int. J. Cancer. 1989. Vol. 43 (5). P. 875–879.Rotheneder M., Kostner G. M. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines // Int. J. Cancer. 1989. Vol. 43 (5). P. 875–879.Pörn M. I., Akerman K. E., Slotte J. P. High-density lipoproteins induce a rapid and transient release of Ca2+ in cultured fibroblasts // Biochem. J. 1991. Vol. 279 (1). P. 29–33.Pörn M. I., Akerman K. E., Slotte J. P. High-density lipoproteins induce a rapid and transient release of Ca2+ in cultured fibroblasts // Biochem. J. 1991. Vol. 279 (1). P. 29–33.Norata G. D., Callegari E., Marchesi M. et al. High-density lipoproteins induce transforming growth factor-2 expression in endothelial cells // Circulation. 2005. Vol. 111. P. 2805–2811.Norata G. D., Callegari E., Marchesi M. et al. High-density lipoproteins induce transforming growth factor-2 expression in endothelial cells // Circulation. 2005. Vol. 111. P. 2805–2811.Tamama K., Tomura H., Sato K. et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component // Atherosclerosis. 2005. Vol. 178. P. 19–23.Tamama K., Tomura H., Sato K. et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component // Atherosclerosis. 2005. Vol. 178. P. 19–23.Norata G. D., Callegari E., Inoue H., Catapano A. L. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 871–877.Norata G. D., Callegari E., Inoue H., Catapano A. L. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 871–877.Nofer J. R., Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids // Trends. Cardiovasc. Med. 2005. Vol. 15. P. 265–271.Nofer J. R., Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids // Trends. Cardiovasc. Med. 2005. Vol. 15. P. 265–271.Nofer J. R., van der Giet M., Tolle M. et al. HDL induces NO-dependent vasorelaxation via the lysophos-pholipid receptor S1P3 // J. Clin. Investig. 2004. Vol. 113. P. 569–581.Nofer J. R., van der Giet M., Tolle M. et al. HDL induces NO-dependent vasorelaxation via the lysophos-pholipid receptor S1P3 // J. Clin. Investig. 2004. Vol. 113. P. 569–581.Deguchi H., Fernandez J. A., Hackeng T. M. et al. Cardiolipin is a normal component of human plasma lipoproteins // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 1743–1748.Deguchi H., Fernandez J. A., Hackeng T. M. et al. Cardiolipin is a normal component of human plasma lipoproteins // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 1743–1748.Calabresi L., Gomaraschi M., Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. 1724–1731.Calabresi L., Gomaraschi M., Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. 1724–1731.Tada N., Sakamoto T., Kagami A. et al. Antimicrobial activity of lipoprotein particles containing apolipoprotein A-I // Mol. And Cell. Biochem. 1993. Vol. 119. P. 171–178.Tada N., Sakamoto T., Kagami A. et al. Antimicrobial activity of lipoprotein particles containing apolipoprotein A-I // Mol. And Cell. Biochem. 1993. Vol. 119. P. 171–178.Agawa Y., Lee S., Ono S. et al. Interaction with phospholipid bilayers, ion channel formation, and antimicrobial activity of basic amphipathic alpha-helical model peptides of various chain lengths // J. Biol. Chem. 1991. Vol. 266 (30). P. 20218–20222.Agawa Y., Lee S., Ono S. et al. Interaction with phospholipid bilayers, ion channel formation, and antimicrobial activity of basic amphipathic alpha-helical model peptides of various chain lengths // J. Biol. Chem. 1991. Vol. 266 (30). P. 20218–20222.Harrington J. M., Howell S., Hajduk S. L. Membrane permeabilization by Trypanosome lytic factor, a cytolytic human high density lipoprotein // J. Biol. Chem. 2009. Vol. 284 (20). P. 13505–13512.Harrington J. M., Howell S., Hajduk S. L. Membrane permeabilization by Trypanosome lytic factor, a cytolytic human high density lipoprotein // J. Biol. Chem. 2009. Vol. 284 (20). P. 13505–13512.Srinivas R. V., Birkedal B., Owens R. J. et al. Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs // Virology. 1990. Vol. 176 (1). P. 48–57.Srinivas R. V., Birkedal B., Owens R. J. et al. Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs // Virology. 1990. Vol. 176 (1). P. 48–57.Hersberger M., von Eckardstein A. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport // Handb. Exp. Pharmacol. 2005. Vol. 170. P. 537–561.Hersberger M., von Eckardstein A. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport // Handb. Exp. Pharmacol. 2005. Vol. 170. P. 537–561.Lewis G. F., Rader D. J. New insights into the regulation of HDL metabolism and reverse cholesterol transport // Circ. Res. 2005. Vol. 96 (12). P. 1221–1232.Lewis G. F., Rader D. J. New insights into the regulation of HDL metabolism and reverse cholesterol transport // Circ. Res. 2005. Vol. 96 (12). P. 1221–1232.Besler C., Heinrich K., Riwanto M. et al. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease // Curr. Pharm. Des. 2010. Vol. 16 (13). P. 1480–1493.Besler C., Heinrich K., Riwanto M. et al. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease // Curr. Pharm. Des. 2010. Vol. 16 (13). P. 1480–1493.Bricarello D. A., Smilowitz J. T., Zivkovic A. M. et al. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures // ACS Nano. 2011. Vol. 5 (1). P. 42–57.Bricarello D. A., Smilowitz J. T., Zivkovic A. M. et al. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures // ACS Nano. 2011. Vol. 5 (1). P. 42–57.Navab M., Ananthramaiah G. M., Reddy S. T. et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL // J. Lipid Res. 2004. Vol. 45. P. 993–1007.Navab M., Ananthramaiah G. M., Reddy S. T. et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL // J. Lipid Res. 2004. Vol. 45. P. 993–1007.Navab M., Yu R., Gharavi N. et al. High-density lipoprotein: antioxidant and anti-inflammatory proper ties // Curr. Atheroscler. Rep. 2007. Vol. 9 (3). P. 244–248.Navab M., Yu R., Gharavi N. et al. High-density lipoprotein: antioxidant and anti-inflammatory proper ties // Curr. Atheroscler. Rep. 2007. Vol. 9 (3). P. 244–248.Nicholls S. J., Dusting G. J., Cutri B. et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits // Circulation. 2005. Vol. 111. P. 1543–1550.Nicholls S. J., Dusting G. J., Cutri B. et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits // Circulation. 2005. Vol. 111. P. 1543–1550.Franceschini G., Sirtori C. R., Capurso A. et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Investig. 1980. Vol. 66. P. 892–900.Franceschini G., Sirtori C. R., Capurso A. et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Investig. 1980. Vol. 66. P. 892–900.Shah P. K., Nilsson J., Kaul S. et al. Effects of recom binant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice // Circulation. 1998. Vol. 97. P. 780–785.Shah P. K., Nilsson J., Kaul S. et al. Effects of recom binant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice // Circulation. 1998. Vol. 97. P. 780–785.Nissen S. E., Tsunoda T., Tuzcu E. M. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial // JAMA. 2003. Vol. 290. P. 2292–2300.Nissen S. E., Tsunoda T., Tuzcu E. M. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial // JAMA. 2003. Vol. 290. P. 2292–2300.White C. R., Datta G., Zhang Z. et al. HDL therapy for cardiovascular diseases: the road to HDL mimetics // Curr. Atheroscler. Rep. 2008. Vol. 10 (5). P. 405–412.White C. R., Datta G., Zhang Z. et al. HDL therapy for cardiovascular diseases: the road to HDL mimetics // Curr. Atheroscler. Rep. 2008. Vol. 10 (5). P. 405–412.Van Lenten B. J., Wagner A. C., Anantharamaiah G. M., et al. Apolipoprotein A-I mimetic peptides // Curr. Atheroscler. Rep. 2009. Vol. 11 (1). P. 52–57.Van Lenten B. J., Wagner A. C., Anantharamaiah G. M., et al. Apolipoprotein A-I mimetic peptides // Curr. Atheroscler. Rep. 2009. Vol. 11 (1). P. 52–57.Zhang Q., Liu L., Zheng X. Y. Protective roles of HDL, apoA-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitor cells // Int. J. Cardiol. 2009. Vol. 133 (3). P. 286–292.Zhang Q., Liu L., Zheng X. Y. Protective roles of HDL, apoA-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitor cells // Int. J. Cardiol. 2009. Vol. 133 (3). P. 286–292.Sherman C. B., Peterson S. J., Frishman W. H. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis // Cardiol. Rev. 2010. Vol. 18 (3). P. 141–147.Sherman C. B., Peterson S. J., Frishman W. H. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis // Cardiol. Rev. 2010. Vol. 18 (3). P. 141–147.D’Souza W, Stonik J. A., Murphy A. et al. Structure / function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein // Circ Res. 2010. Vol. 107 (2). P. 217–227.D’Souza W, Stonik J. A., Murphy A. et al. Structure / function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein // Circ Res. 2010. Vol. 107 (2). P. 217–227.Sethi A. A., Stonik J. A., Thomas F. et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides // J. Biol. Chem. 2008. Vol. 283 (47). P. 32273–32282.Sethi A. A., Stonik J. A., Thomas F. et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides // J. Biol. Chem. 2008. Vol. 283 (47). P. 32273–32282.Navab M., Reddy S. T., Anantharamaiah G. M. et al. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice // J. Lipid. Res. 2012. Vol. 53 (3). P. 437–445.Navab M., Reddy S. T., Anantharamaiah G. M. et al. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice // J. Lipid. Res. 2012. Vol. 53 (3). P. 437–445.Bloedon L. T., Dunbar R., Duffy D. et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients // J. Lipid. Res. 2008. Vol. 49 (6). P. 1344–1352.Bloedon L. T., Dunbar R., Duffy D. et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients // J. Lipid. Res. 2008. Vol. 49 (6). P. 1344–1352.Navab M., Shechter I., Anantharamaiah G. M., et al. Structure and function of HDL mimetics // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30 (2). P. 164–168.Navab M., Shechter I., Anantharamaiah G. M., et al. Structure and function of HDL mimetics // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30 (2). P. 164–168.

The authors declare that there are no conflicts of interest present.